Comparative effectiveness against other antidiabetic agents: Several studies have highlighted that GLP-1RAs reduce the risk of obesity-related cancers, including HCC, compared with insulin use [20,21,24]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.